Posttransplant immunosuppression in highly sensitized patients

Contributions to Nephrology

Volumn 162, Issue , 2009, Pages 27-34

  Akalin, Enver ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; REVIEW; SPLENECTOMY;

B-LYMPHOCYTES; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; SPLENECTOMY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 59849117803     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000170810     Document Type: Article

References (30)

1. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
2. Jordan S, Cunningham-Rundles C, McEwan R: Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003;3:653-664.
3. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-3262.
4. Watanabe J, Scornik JC: IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005;5:2786-2790.
5. 2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003;9:431-438.
6. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-486.
7. Park-Min KH, Serbina NV Yang W, Ma X, Krystal G, Neel BG, et al: FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin. Immunity 2007;26:67-78.
8. Pescovitz MD: Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-866.
9. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, et al: Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003;76:631-636.
10. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC: Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006;6:2384-2390.
11. Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, et al: Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008;8:144-149.
12. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, et al: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002;2:758-760.
13. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-1977.
14. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006;82: 1387-1395.
15. Montgomery RA, Zachary AA: Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004;8:535-542.
16. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-895.
17. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, et al: Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003;76:1519-1525.
18. Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A, et al: A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000;70:1531-1536.
19. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S: A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346-351.
20. Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL, et al: Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003;3:1017-1023.
21. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Buhler R, et al: Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996;348:1208-1211.
22. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, et al: Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005;79:696-701.
23. Akalin E, Bromberg JS: Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005;66:359-363.
24. Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, et al: Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003;76:1444-1447.
25. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS, Fotino M, et al: Intravenous immunoglobu-lin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 2005;79:742.
26. Akalin E, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Sehgal V, et al: Addition of plasma-pheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008;3:1160-1167.
27. Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, et al: The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007;7:1027-1031.
28. Gloor JM, DeGoey S, Ploeger N, Gebel H, Bray R, Moore SB, et al: Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004;78:221-227.
29. Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, et al: Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006;6:1841-1847.
30. Anglicheau D, Loupy A, Suberbielle C, Zuber J, Patey N, Noel LH, et al: Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant 2007;7:1185-1192.